New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer

Dateline City:

KENILWORTH, N.J.

Data at ASCO Evaluates KEYTRUDA As Single Agent and in Novel Combinations in More Than 15 Different Cancers, Including Several New Tumors

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that new and updated data investigating KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 therapy, in more than 15 types
of cancer will be presented at the 52nd Annual Meeting of the
American Society of Clinical Oncology (ASCO) in Chicago, June 3 – 7,
2016.

Language:

English

Contact:

MerckMedia:Pamela Eisele, [phone]Kim Hamilton, [phone]orInvestor:Teri Loxam, [phone]Justin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Research and Development News - May 16, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news